CompletedNot Applicable

Platelet Reactivity in Patients on a Thienopyridine and Awaiting Coronary Artery Bypass Grafting

75 participantsStarted 2010-08

Plain-language summary

The primary objective of this exploratory cohort study is to describe levels of platelet reactivity in patients on a thienopyridine awaiting coronary artery bypass grafting (CABG).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients ≥ 18 years old from both genders.
✓. Taking maintenance thienopyridine therapy within 5 days of surgery OR received a loading dose of thienopyridine therapy within 48 hours of surgery for CABG.
✓. Referred for CABG (which is scheduled to be performed during the current admission).

Exclusion criteria

✕. Known allergies to aspirin, clopidogrel, or prasugrel.
✕. Use of a glycoprotein (GP) IIb/IIIa inhibitor within 8 hours of initial platelet reactivity testing.
✕. Patient known to be pregnant or lactating.
✕. Patient with known history of bleeding diathesis or currently active bleeding.
✕. Platelet count \<100,000/mm the day of initial blood draw.
✕. Hematocrit \<25% the day of initial blood draw.
✕. On warfarin therapy at the time of initial blood draw.
✕. Known blood transfusion within the preceding 10 days of the blood draw.

What they're measuring

Serial levels of platelet reactivity, as assessed with the Chrono-log Lumi-Aggregometer

Timeframe: Duration of hospital stay; average hospital stay of 1 week

Perioperative rates of bleeding complications

Timeframe: Duration of hospital stay; average hospital stay of 1 week

Trial details

NCT IDNCT01406483

SponsorMedstar Health Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-02

View on ClinicalTrials.gov More Complication of Coronary Artery Bypass Graft trials